Johnson & Johnson's drug Zytiga slowed the growth of prostate cancer in a clinical trial of men who hadn't undergone chemotherapy.
WSJ.com: What's News US, Wall Street Journal
Sat, 06/02/2012 - 5:04pm
Johnson & Johnson's drug Zytiga slowed the growth of prostate cancer in a clinical trial of men who hadn't undergone chemotherapy.